rosiglitazone has been researched along with Kidney Diseases in 17 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (5.88) | 18.2507 |
| 2000's | 9 (52.94) | 29.6817 |
| 2010's | 5 (29.41) | 24.3611 |
| 2020's | 2 (11.76) | 2.80 |
| Authors | Studies |
|---|---|
| Chen, H; Deng, J; Shao, X; Wang, X; Xia, Y; Xiong, C; Zhou, Q; Zou, H | 1 |
| Shi, Z; Wei, S; Wu, M; Xu, C; Yang, B; Zhang, Y | 1 |
| Chodavarapu, H; Elased, KM; Grobe, N; Madhu, M; Salem, ES; Somineni, HK | 1 |
| Barua, CC; Bezbaruah, B; Gaikwad, AB; Kumar, P; Prashanth, KS; Vij, M | 1 |
| Czechowska, G; Dudka, J; Korolczuk, A; Maciejewski, M; Smolen, A; Widelska, I | 1 |
| Bai, M; Chen, Y; Ding, G; Huang, S; Jia, Z; Xu, Y; Zhang, A; Zhang, Y; Zhao, M | 1 |
| Andrade, L; Libório, AB; Pereira, LV; Sanches, TR; Seguro, AC; Shimizu, MH | 1 |
| Glover, PH; Jones, AV; Maric, C; McLemore, GR; Racusen, LC; Reckelhoff, JF; Ryan, MJ; Sartori-Valinotti, JC; Venegas-Pont, M | 1 |
| Gupta, J; Kumar, P; Tikoo, K | 1 |
| Cekmen, M; Ilbey, YO; Mete, F; Ozbek, E; Simsek, A; Somay, A | 1 |
| Jang, KY; Jang, YB; Kang, KP; Kim, DH; Kim, W; Lee, JE; Lee, S; Moon, SO; Park, SK; Sung, MJ | 1 |
| Cai, L; Li, C; Li, X; Yu, X | 1 |
| Adler, S; Banz, W; Cho, KW; Davis, J; Higginbotham, A; Kim, YC; Moustaid-Moussa, N; O'Connor, T; Peterson, R; Shay, N; Tebbe, A | 1 |
| Ahn, KO; Choi, BS; Ito, S; Kim, J; Kim, YS; Li, C; Lim, SW; Sugawara, A; Yang, CW; Yang, HJ | 1 |
| Dülger, GA; Gedik, N; Sehirli, AO; Sener, G | 1 |
| Al-Barazanji, KA; Bond, B; Buckingham, RE; Clapham, JC; Connor, SC; Slaughter, M; Toseland, CD; Turner, NC; West, A | 1 |
| Bakris, G | 1 |
17 other study(ies) available for rosiglitazone and Kidney Diseases
| Article | Year |
|---|---|
Treatment with a PPAR-γ Agonist Protects Against Hyperuricemic Nephropathy in a Rat Model.
Topics: Administration, Oral; Animals; Disease Models, Animal; Hyperuricemia; Kidney Diseases; Male; Neuroprotective Agents; PPAR gamma; Rats; Rats, Sprague-Dawley; Rosiglitazone | 2020 |
Ultrasound Assisted a Peroxisome Proliferator-Activated Receptor (PPAR)γ Agonist-Loaded Nanoparticle-Microbubble Complex to Attenuate Renal Interstitial Fibrosis.
Topics: Animals; Drug Delivery Systems; Fibrosis; Kidney; Kidney Diseases; Male; Mice; Microbubbles; Nanoparticles; Polylactic Acid-Polyglycolic Acid Copolymer; PPAR gamma; Rats, Sprague-Dawley; Rosiglitazone; Tissue Distribution; Ultrasonography | 2020 |
Rosiglitazone treatment of type 2 diabetic db/db mice attenuates urinary albumin and angiotensin converting enzyme 2 excretion.
Topics: ADAM Proteins; ADAM17 Protein; Albuminuria; Angiotensin-Converting Enzyme 2; Animals; Blood Glucose; Diabetes Mellitus, Type 2; Disease Models, Animal; Glucagon; Glucose Tolerance Test; Glycosuria; Hyperglycemia; Hypoglycemic Agents; Kidney Diseases; Male; Membrane Proteins; Mice; Peptidyl-Dipeptidase A; Rosiglitazone; Thiazolidinediones; Tissue Inhibitor of Metalloproteinase-3; Triglycerides | 2013 |
Disparity in actions of rosiglitazone against cisplatin-induced nephrotoxicity in female Sprague-Dawley rats.
Topics: Animals; Antineoplastic Agents; Blood Urea Nitrogen; Body Weight; Cisplatin; Creatinine; Female; Hypoglycemic Agents; Kidney; Kidney Diseases; Kidney Function Tests; Organ Size; Rats; Rats, Sprague-Dawley; Rosiglitazone; Serum Albumin; Thiazolidinediones; Tumor Necrosis Factor-alpha | 2013 |
The role of peroxisome-proliferator-activating receptor gamma agonists: rosiglitazone and 15-deoxy-delta12,14-prostaglandin J2 in chronic experimental cyclosporine A-induced nephrotoxicity.
Topics: Animals; Creatinine; Cyclosporine; Disease Models, Animal; Glutathione; Glutathione Disulfide; Kidney; Kidney Diseases; Male; NAD; NADP; PPAR gamma; Prostaglandin D2; Protective Agents; Rats, Wistar; Rosiglitazone; Thiazolidinediones; Urea; Uric Acid | 2014 |
Renal tubular epithelium-targeted peroxisome proliferator-activated receptor-γ maintains the epithelial phenotype and antagonizes renal fibrogenesis.
Topics: Animals; Cells, Cultured; Fibrosis; Humans; Kidney; Kidney Diseases; Male; Mice; Mice, Inbred C57BL; Mice, Knockout; Oxidative Stress; Phenotype; PPAR gamma; Prostaglandin D2; Rosiglitazone; Signal Transduction; Thiazolidinediones; Transforming Growth Factor beta1; Urothelium | 2016 |
Rosiglitazone reverses tenofovir-induced nephrotoxicity.
Topics: Adenine; Animals; Drug-Related Side Effects and Adverse Reactions; Glomerular Filtration Rate; Hypoglycemic Agents; Hypophosphatemia; Hypophosphatemia, Familial; Kidney Diseases; Male; Membrane Transport Proteins; Organophosphonates; Rats; Rats, Wistar; Reverse Transcriptase Inhibitors; Rosiglitazone; Tenofovir; Thiazolidinediones | 2008 |
Rosiglitazone decreases blood pressure and renal injury in a female mouse model of systemic lupus erythematosus.
Topics: Albuminuria; Animals; Antihypertensive Agents; Blood Pressure; Chemokine CCL2; Disease Models, Animal; Endothelin-1; Female; Hypertension; Kidney; Kidney Diseases; Lupus Erythematosus, Systemic; Macrophages; Mice; Monocytes; Osteopontin; PPAR gamma; RNA, Messenger; Rosiglitazone; Thiazolidinediones | 2009 |
Rosiglitazone synergizes anticancer activity of cisplatin and reduces its nephrotoxicity in 7, 12-dimethyl benz{a}anthracene (DMBA) induced breast cancer rats.
Topics: 9,10-Dimethyl-1,2-benzanthracene; Animals; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Blood Urea Nitrogen; Blotting, Western; Body Weight; Cisplatin; Creatinine; Drug Synergism; Enzyme-Linked Immunosorbent Assay; Histones; Kidney; Kidney Diseases; Mammary Glands, Animal; Mammary Neoplasms, Experimental; p38 Mitogen-Activated Protein Kinases; Phosphorylation; PPAR gamma; Rats; Rats, Sprague-Dawley; Rosiglitazone; Serum Albumin; Thiazolidinediones; Tumor Burden; Tumor Necrosis Factor-alpha | 2009 |
Rosiglitazone, peroxisome proliferator receptor-gamma agonist, ameliorates gentamicin-induced nephrotoxicity in rats.
Topics: Aminoglycosides; Animals; Anti-Bacterial Agents; Gentamicins; Kidney; Kidney Diseases; Kidney Tubules; Male; PPAR gamma; Rats; Rats, Wistar; Rosiglitazone; Thiazolidinediones | 2010 |
Rosiglitazone ameliorates cisplatin-induced renal injury in mice.
Topics: Anilides; Animals; Apoptosis; C-Peptide; Cell Line; Chromans; Cisplatin; Drug Evaluation, Preclinical; Glioma; Humans; Hypoglycemic Agents; Inflammation; Insulin; Intercellular Adhesion Molecule-1; Kidney; Kidney Diseases; Kidney Function Tests; Kidney Tubules, Proximal; Macrophages; Male; Mice; Mice, Inbred C57BL; Monocytes; PPAR gamma; Prostaglandin D2; Protein Transport; Rosiglitazone; Thiazolidinediones; Transcription Factor RelA; Troglitazone; Tumor Necrosis Factor-alpha | 2006 |
Rosiglitazone prevents advanced glycation end products-induced renal toxicity likely through suppression of plasminogen activator inhibitor-1.
Topics: Animals; Blotting, Western; Cells, Cultured; Collagen Type IV; Fibronectins; Gene Expression; Glycation End Products, Advanced; Hypoglycemic Agents; Immunohistochemistry; Kidney; Kidney Diseases; Male; Mesangial Cells; Microscopy, Electron; Plasminogen Activator Inhibitor 1; PPAR gamma; Rats; Rats, Wistar; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; Rosiglitazone; Thiazolidinediones | 2007 |
Soy protein and isoflavones influence adiposity and development of metabolic syndrome in the obese male ZDF rat.
Topics: Adiposity; Animals; Blood Glucose; Caseins; Hypoglycemic Agents; Isoflavones; Kidney Diseases; Liver; Male; Metabolic Syndrome; Milk Proteins; Obesity; Proteinuria; Rats; Rats, Inbred Strains; Rosiglitazone; Soybean Proteins; Thiazolidinediones | 2007 |
Induction of PPAR gamma mRNA and protein expression by rosiglitazone in chronic cyclosporine nephropathy in the rat.
Topics: Animals; Cyclosporine; Disease Models, Animal; Gene Expression Regulation; Kidney Diseases; Male; PPAR gamma; Protein Biosynthesis; Rats; Rats, Sprague-Dawley; RNA, Messenger; Rosiglitazone; Thiazolidinediones; Transcription, Genetic | 2007 |
Rosiglitazone, a PPAR-gamma ligand, protects against burn-induced oxidative injury of remote organs.
Topics: Alanine Transaminase; Animals; Aspartate Aminotransferases; Burns; Female; Hypoglycemic Agents; Interleukin-1beta; Kidney Diseases; L-Lactate Dehydrogenase; Liver Diseases; Male; Malondialdehyde; Oxidative Stress; Peroxidase; Rats; Rats, Wistar; Rosiglitazone; Thiazolidinediones; Tumor Necrosis Factor-alpha; Urea | 2007 |
Peroxisome proliferator-activated receptor-gamma agonist, rosiglitazone, protects against nephropathy and pancreatic islet abnormalities in Zucker fatty rats.
Topics: Acetylglucosaminidase; Albuminuria; Animals; Blood Pressure; Body Weight; Histocytochemistry; Hypoglycemic Agents; Immunohistochemistry; Islets of Langerhans; Kidney; Kidney Diseases; Male; Obesity; Pancreas; Pancreatic Diseases; Proteinuria; Rats; Rats, Zucker; Rosiglitazone; Systole; Thiazoles; Thiazolidinediones | 1998 |
Oral antidiabetic agents safe with renal disease?
Topics: Aged; Contraindications; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Humans; Hypoglycemic Agents; Kidney Diseases; Metformin; Rosiglitazone; Thiazoles; Thiazolidinediones | 2000 |